Anavex will likely be bought out in less than 2 years at a small fraction of what it is worth, because two men with no bio background whatsoever have taken the roll of deciding what market cap each emerging biotech shall be able to maintain. Cramer, Feuestein, and Feuerstein-II / Martin Shkreli are in nearly complete control, using the highly illegal tactics that you blow-off by saying, "Who gives a f---k".
If you add Feuerstein's widely publicised and circulated "Thesis" (his BA Thesis?) which states that emerging biotechs with less than $300M market caps are doomed to fail, then these men are not just controlling how easy life will be for emerging biotechs, but whether they will survive at all. On the verge of collapse, these companies either get aquired on the cheap by the big pharma's in these men's hedge funds / associates' hedge funds, or they die and their threat of competition is gone.
Anavex is absolutely a major threat to Axon. Just as NWBO is a major threat to Celldex, one of Jim Cramer's darlings. If you examine Cramer's recommendations and the holdings in his associate's hedge funds, as well as the holding's in Martin Shrikeli's hedge fund, I am willing to bet that Axon is a major holding.
Two or three men, tightly connected. Feuerstein's first job in the Biotech Arena was working for Cramer as a "Biotech Reporter". Martin Shkreli's first job period, was working for four years as an intern at Cramer's hedge fund. They both learned from the master. The master of what? According to Cramer, among other things, the master of stock price manipulation via circulation of damaging, false rumors, when it serves the hedge fund's purposes. Cramer is an admitted big time securities crook who managed to escape prison and land a job as the most widely watched stock advisor on the planet, because he has connections to people in positions of power.
Anavex was getting overhyped, and whoever drove the Agora Financial article should be fired or shot... but the fact is, there is no real reason to believe that Anavex had anything to do with that. As a long investor, I have watched CEO Missling in his interviews and conference webcasts, and I have consistently witnessed him understate expectations of efficacy. His standard line is that we just have to go through the trials and wait and see.
That said, I have to back off from saying how impressed I am with the recently circulated chart showing impressive efficacy for Anavex 2-73 Plus (75% Plus, 25% w/o adjunct generic) through 16 or 18 weeks. I don't understand the chart. My knee jerk was to be very impressed, and I put on the back burner trying to understand the textual explanations under the chart... but after three brief tries, I admit, I have no idea what that chart is showing. It is very impressive, but what is it? It's frankendata. A mix of data from different tests? I don't think it is in the best interest of the company to circulate an impressive looking chart that is so confusing. But I don't think Anavex did cirulate the chart. I am confused about all that. Looks like a technical individual put that together, and it might be very meaningful, but I shouldn't say that it is, because, I don't understand it.
The chart is very important because the criticism that 5 week data is not super meaningfull is a legitimate criticism. It is wonderful that the 5 week data looks good, but the critics are right that 10 cups of coffee, or maybe 3, might have good results at 5 weeks. But not at 18 weeks. There would be burnout by 18 weeks. Certainly not a consistent, continuing increase in efficacy, as that frankenchart showed. So... I agree that the 24 week data (or 26) is super important, and that the proper SP/cap is difficult to determine until then, but I don't agree that it is Cramer, Feuerstein, and Skreli's right to set that $Value using their tremendous reach and outright lies. That is flatly illegal and should be dealt with as such. Those three people people are fkng nobody!
News 
Market Data 
Discover 
